Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IDEC Rituxin

Executive Summary

Rituximab receives "complete review" letter Sept. 19 for expanded non-Hodgkin's lymphoma indication including eight weekly doses per treatment, multiple courses of treatment and treatment of patients with bulky disease. FDA requested inclusion of two safety and efficacy tables in the product package insert. IDEC submitted the supplemental BLA Oct. 29, 1999; Rituxin was approved in 1997 for the treatment of patients with relapsed or refractory, low grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma

You may also be interested in...



Genentech/Idec Rituxan Letter Warns Of Fatal Mucocutaneous Reactions

Fatal mucocutaneous reactions to Genentech/Idec's Rituxan non-Hodgkin's lymphoma treatment are the subject of a "Dear Healthcare Provider" letter sent to oncologists May 8.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel